Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 303 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "ALK" Clear all
Completed Phase 1 Interventional Results available

A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors

NCT01999972
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
axitinib, crizotinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
15
States / cities
Chicago, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Results available

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

NCT01979536
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma
Interventions
Brentuximab Vedotin, Crizotinib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
154
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 117 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Jul 23, 2026, 5:00 PM EDT
Active, not recruiting Phase 2 Interventional

Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

NCT03786692
View directory record Official record
Conditions
Non-Small Cell Carcinoma of Lung, TNM Stage 4
Interventions
Arm A, Arm B
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

NCT05004116
View directory record Official record
Conditions
Advanced Cancer, Metastatic Solid Tumor
Interventions
Repotrectinib, Irinotecan and temozolomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year to 25 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

NCT02349633
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
PF-06747775, Palbociclib, Avelumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
7
States / cities
La Jolla, California • San Diego, California • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults

NCT03409276
View directory record Official record
Conditions
HIV Infections
Interventions
env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, Placebo, GLA-SE adjuvant
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
6
States / cities
Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Jul 23, 2026, 5:00 PM EDT
Terminated Phase 4 Interventional

Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC

NCT05583188
View directory record Official record
Conditions
NSCLC
Interventions
Aliya Pulsed Electric Fields (PEF) ablation, Nivolumab plus Platinum Doublet Chemotherapy, Standard of care neoadjuvant therapy, Surgical Resection
Device · Drug · Other
Lead sponsor
Galvanize Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 4 Interventional Results available

Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.

NCT00570492
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Fluticasone furoate nasal spray, Placebo nasal spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 8 Years
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
50
States / cities
Oxford, Alabama • Little Rock, Arkansas • Huntington Beach, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Jul 23, 2026, 5:00 PM EDT
Recruiting Phase 3 Interventional

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

NCT06724237
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Best Practice, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, High Dose Chemotherapy, Leukapheresis, Positron Emission Tomography, Stem Cell Mobilization Therapy
Procedure · Other · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 75 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
158
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 117 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 1 Interventional Results available

A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

NCT01283516
View directory record Official record
Conditions
Tumors Characterized by Genetic Abnormalities of ALK
Interventions
LDK378
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Jul 23, 2026, 5:00 PM EDT
Withdrawn Early Phase 1 Interventional

Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations

NCT02277457
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
PET-Adaptive RT, Erlotinib, Crizotinib
Radiation · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Jul 23, 2026, 5:00 PM EDT
Terminated Phase 2 Interventional Results available

A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)

NCT03170232
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin 35 mg tablets, Placebo, Metered dose inhaler (MDI) sensor device, Rescue medication
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 76 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Birmingham, Alabama • San Diego, California • Torrance, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 3 Interventional Results available

A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

NCT03596866
View directory record Official record
Conditions
ALK+ Advanced NSCLC
Interventions
Brigatinib, Alectinib
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Whittier, California • Athens, Georgia • Albany, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Jul 23, 2026, 5:00 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

NCT07491497
View directory record Official record
Conditions
ALK-positive NSCLC, ALK-Positive Lung Cancer, ALK-positive Non-small Cell Lung Cancer
Interventions
TRI-611
Drug
Lead sponsor
TRIANA Biomedicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
11
States / cities
San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

NCT03093116
View directory record Official record
Conditions
Locally Advanced Solid Tumors, Metastatic Solid Tumors
Interventions
Oral repotrectinib (TPX-0005)
Drug
Lead sponsor
Turning Point Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
49
States / cities
Duarte, California • Glendale, California • La Jolla, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 3 Interventional Results available

M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

NCT03631706
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
M7824, Pembrolizumab
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
25
States / cities
Huntsville, Alabama • Los Angeles, California • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Jul 23, 2026, 5:00 PM EDT
Active, not recruiting Phase 1 Interventional

Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

NCT03707938
View directory record Official record
Conditions
Advanced Lung Carcinoma, ALK Gene Rearrangement, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Brigatinib, Local Consolidation Therapy
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Jul 23, 2026, 5:00 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors

NCT02706626
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
brigatinib
Drug
Lead sponsor
Criterium, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Denver, Colorado • Durham, North Carolina • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Jul 23, 2026, 5:00 PM EDT
Terminated Phase 2 Interventional Results available

Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)

NCT02186821
View directory record Official record
Conditions
Tumors With Aberrations in ALK or ROS1
Interventions
Ceritinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
21
States / cities
Santa Rosa, California • Denver, Colorado • Greenwood Village, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Jul 23, 2026, 5:00 PM EDT
Active, not recruiting Phase 1 Interventional

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

NCT02321501
View directory record Official record
Conditions
ALK Positive, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, ROS1 Gene Rearrangement, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Ceritinib, Everolimus, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Recruiting No phase listed Observational

An External Control Arm Study in Non-Small Cell Lung Cancer

NCT07174388
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
N-Power Medicine
Industry
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Monterey, California • Dover, Delaware • Milford, Delaware + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Terminated Phase 2 Interventional Results available

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

NCT02587650
View directory record Official record
Conditions
ALK Fusion Protein Expression, BRAF wt Allele, Invasive Skin Melanoma, MET Fusion Gene Positive, NRAS wt Allele, NTRK1 Fusion Positive, NTRK2 Fusion Positive, NTRK3 Fusion Positive, RET Fusion Positive, ROS1 Fusion Positive, Stage III Cutaneous Melanoma, Stage IIIA Cutaneous Melanoma, Stage IIIB Cutaneous Melanoma, Stage IIIC Cutaneous Melanoma, Stage IV Cutaneous Melanoma
Interventions
Capmatinib, Ceritinib, Entrectinib, Laboratory Biomarker Analysis, Regorafenib
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent

NCT02689206
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863, GSK1278863 matching Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Northridge, California • San Dimas, California • Pembroke Pines, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Jul 23, 2026, 5:00 PM EDT
Not listed Not applicable Interventional

The Effect of Vitamin D Repletion in Patients With Hepatocellular Carcinoma on the Orthotopic Liver Transplant List

NCT01575717
View directory record Official record
Conditions
Vitamin D Deficiency, Hepatocellular Carcinoma
Interventions
Vitamin D3 4000 IU, Vitamin D3 2000 IU
Drug
Lead sponsor
Andrea Branch
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Jul 23, 2026, 5:00 PM EDT